Sec Form 4 Filing - ATWOOD BRIAN G @ Immune Design Corp. - 2014-07-29

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person ATWOOD BRIAN G 2. Issuer Name and Ticker or Trading Symbol Immune Design Corp. [ IMDZ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E., SUITE 310 3. Date of Earliest Transaction (MM/DD/YY) 07/29/2014 (Street) SEATTLE, WA98102 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/29/2014 C 733,941 A 733,941 I ( 2 ) See Footnote ( 2 ) Common Stock 07/29/2014 C 531,840 A 1,265,781 I ( 2 ) See Footnote ( 2 ) Common Stock 07/29/2014 C 611,620 A 1,877,401 I ( 2 ) See Footnote ( 2 ) Common Stock 07/29/2014 C 305,810 A 2,183,211 I ( 2 ) See Footnote ( 2 ) Common Stock 07/29/2014 S( 4 ) 208,334 D $ 12 1,974,877 I ( 2 ) See Footnote ( 2 ) Common Stock 07/29/2014 P 233,333 A $ 12 2,208,210 I ( 2 ) See Footnote ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Preferred Stock ( 1 ) 07/29/2014 C 733,941 ( 1 ) ( 1 ) Common Stock 733,941 $ 0 0 I ( 2 ) See Footnote ( 2 ) Series B Preferred Stock ( 1 ) 07/29/2014 C 531,840 ( 1 ) ( 1 ) Common Stock 531,840 $ 0 0 I ( 2 ) See footnote ( 2 ) Series C Preferred Stock ( 1 ) 07/29/2014 C 611,620 ( 1 ) ( 1 ) Common Stock 611,620 $ 0 0 I ( 2 ) See Footnote ( 2 ) Series C Preferred Stock Warrant (right to buy) $ 8.175 07/29/2014 X 305,810 10/16/2013 ( 3 ) Series C Preferred Stock 305,810 $ 0 0 I ( 2 ) See footnote ( 2 ) Series C Preferred Stock ( 1 ) 07/29/2014 X 305,810 ( 1 ) ( 1 ) Common Stock 305,810 $ 0 305,810 I ( 2 ) See Footnote ( 2 ) Series C Preferred Stock ( 1 ) 07/29/2014 C 305,810 ( 1 ) ( 1 ) Common Stock 305,810 $ 0 0 I ( 2 ) See Footnote ( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other ATWOOD BRIAN G C/O IMMUNE DESIGN CORP. 1616 EASTLAKE AVE. E., SUITE 310 SEATTLE, WA98102 X X Signatures /s/ Laura A. Berezin, Attorney-in-Fact 07/31/2014 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. ( 2 )The securities are directly held by Versant Venture Capital III, L.P. and Versant Side Fund III, L.P. (collectively, the "Versant Entities"). Mr. Atwood is a managing member of Versant Ventures III, L.L.C., the sole general partner of the Versant Entities and may be deemed to have shared voting and dispositive power over the shares owned by the Versant Entities. Mr. Atwood disclaims beneficial ownership of all shares held by the Versant Entities, except to the extent of his actual pecuniary interest therein. ( 3 )The warrants were set to expire on the earlier of: (a) October 15, 2015, (b) the latter of (i) 30 days after delivery to the warrant holder of the interim study report of a specified clinical trial by the Issuer or (ii) 30 days after notice to the warrant holder of the commencement of patient recruitment for specified studies or trials by the Issuer, (c) a liquid ation event of the Issuer or (d) the closing of the Issuer's initial public offering. ( 4 )Immediately prior to the closing of the Issuer's initial public offering, the reporting person exercised a warrant to purchase 305,810 shares of the Issuer's Series C preferred stock for $8.175 per share, which then immediately converted into 305,810 shares of the Issuer's common stock. The reporting person paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 208,334 shares of the Issuer's common stock to pay the exercise price and issuing to the reporting person the remaining 97,476 shares of common stock.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.